Gilead Sciences Files Q1 2025 10-Q Report
Ticker: GILD · Form: 10-Q · Filed: 2025-05-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Gilead dropped its Q1 2025 10-Q. Check financials.
AI Summary
Gilead Sciences, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and business segments are presented, reflecting the company's ongoing activities in the biopharmaceutical sector.
Why It Matters
This report provides investors and analysts with the latest financial and operational details from Gilead Sciences, crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial updates, not indicating any immediate or significant new risks.
Key Numbers
- 2025-03-31 — Reporting Period End (The end date for the financial reporting period covered by this 10-Q.)
- 2025-05-07 — Filing Date (The date this 10-Q report was officially filed with the SEC.)
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Filer
- 20250331 (date) — Reporting period end date
- 20250507 (date) — Filing date
- 333 LAKESIDE DR (address) — Company business and mailing address
- FOSTER CITY, CA 94404 (address) — Company business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q report filed with the SEC?
This 10-Q report was filed on May 7, 2025.
What is the company's primary business address?
The company's primary business address is 333 Lakeside Dr, Foster City, CA 94404.
What is the fiscal year end for Gilead Sciences, Inc.?
The fiscal year end for Gilead Sciences, Inc. is December 31.
What is the SIC code for Gilead Sciences, Inc.?
The Standard Industrial Classification (SIC) code for Gilead Sciences, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
From the Filing
0000882095-25-000012.txt : 20250507 0000882095-25-000012.hdr.sgml : 20250507 20250507163249 ACCESSION NUMBER: 0000882095-25-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 25921996 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 10-Q 1 gild-20250331.htm FORM 10-Q gild-20250331 0000882095 12/31 2025 Q1 false 365 729 455 iso4217:USD xbrli:shares xbrli:shares iso4217:USD iso4217:EUR xbrli:pure gild:designee gild:patent gild:claim gild:lawsuit gild:plaintiff gild:segment 0000882095 2025-01-01 2025-03-31 0000882095 2024-12-31 0000882095 2025-03-31 0000882095 2025-04-30 0000882095 us-gaap:ProductMember 2025-01-01 2025-03-31 0000882095 us-gaap:ProductMember 2024-01-01 2024-03-31 0000882095 gild:RoyaltyContractAndOtherMember 2025-01-01 2025-03-31 0000882095 gild:RoyaltyContractAndOtherMember 2024-01-01 2024-03-31 0000882095 2024-01-01 2024-03-31 0000882095 us-gaap:CommonStockMember 2024-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000882095 us-gaap:RetainedEarningsMember 2024-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2024-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000882095 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000882095 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000882095 us-gaap:CommonStockMember 2025-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000882095 us-gaap:RetainedEarningsMember 2025-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2025-03-31 0000882095 us-gaap:CommonStockMember 2023-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000882095 us-gaap:RetainedEarningsMember 2023-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-12-31 0000882095 2023-12-31 0000882095 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000882095 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000882095 us-gaap:CommonStockMember 2024-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000882095 us-gaap:RetainedEarningsMember 2024-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2024-03-31 0000882095 2024-03-31 0000882095 country:US gild:HIVProductsBiktarvyMember 2025-01-01 2025-03-31 0000882095 srt:EuropeMember gild:HIVProductsBiktarvyMember 2025-01-01 2025-03-31 0000882095 gild:RestOfWorldMember gild:HIVProductsBiktarvyMember 2025-01-01 2025-03-31 0000882095 gild:HIVProductsBiktarvyMember 2025-01-01 2025-03-31 0000882095 country:US gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 srt:EuropeMember gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 gild:RestOfWorldMember gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 country:US gild:HIVProductsDescovyMember 202